NATICK, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today released data reflecting experience from the first 15,000 patients(1) monitored wirelessly on the LATITUDE® Patient Management System. This event data represents the industry's largest experience with wireless remote monitoring of implantable cardiac devices. The LATITUDE Patient Management system can detect clinical events between scheduled follow-up visits and then send the clinical event data directly to physicians. Virtually all Boston Scientific ICD and CRT-D patients are eligible to be enrolled on LATITUDE. To date, more than 60,000 patients are enrolled on the system at more than 1,300 clinics across the United States.
Of the nearly 106,000 monitoring months included in the 15,000-patient population, over a mean follow-up of seven months, the LATITUDE Patient Management system detected 948 patients with at least one event of sustained atrial arrhythmia for more than 24 hours. Patients with atrial fibrillation, particularly those with heart failure, are at risk of stroke. By identifying this arrhythmia earlier, physicians can intervene with treatments to lessen this risk. The LATITUDE Patient Management system also detected 1,516 patients who received at least one event of shock therapy for potentially life threatening arrhythmias.
"Remote monitoring between regularly scheduled follow-ups may enable clinicians to observe these events sooner in their device patients, which gives physicians the option to intervene earlier," said Mark A. Silver, M.D., Director, Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL. "Equally important is regular monitoring of a patient's weight and blood pressure, which are key indicators of potential heart failure in patients." Heart failure has an annual direct cost of more than $26 billion in the U.S.
Available as an optional component to the LATITUDE Patient Management system is the industry's first and only wireless weight scale and blood pressure cuff, which is aligned with the ACC/AHA physician society guidelines that recommend monitoring weight and blood pressure. LATITUDE also offers custom views with relevant clinical data to both the implanting and health care following physicians. This feature, combined with passive event notification, is designed to improve patient care.
The LATITUDE Patient Management system will be demonstrated during the Heart Failure Society of America (HFSA) Conference, September 16-19, in Washington, DC.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, significance of event data, our growth strategy, our operational strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A -- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: Paul Donovan 508-650-8541 (office) 508-667-5165 (mobile) Media Relations Boston Scientific Corporation Dan Brennan 508-650-8538 (office) 617-459-2703 (mobile) Investor Relations Boston Scientific Corporation
(1)Analysis of aggregate de-identified LATITUDE Patient Management System data for the initial 15,000 patients with wireless systems as of 8/29/07. Data on file.
SOURCE: Boston Scientific Corporation
CONTACT: Media Relations, Paul Donovan, +1-508-650-8541 Office,
+1-508-667-5165 Mobile; or Investor Relations, Dan Brennan,
+1-508-650-8538 Office, +1-617-459-2703 Mobile
Web site: http://www.bostonscientific.com/